A Welsh biotech firm will today unveil fresh data which suggests its drug delivery technology can help treat serious neurological illnesses such as Parkinson’s disease and Huntington’s disease.
ReNeuron said the results of its latest studies provided ‘clear pre-clinical proof-of-concept’ that its exosome technology can deliver therapeutic proteins to the corpus striatum, a region of the brain that is affected by disabling neurological diseases and strokes.
Exosomes are microscopic fluid-filled sacs that transport molecules between cells in the human body.
Study: ReNeuron said the results of its latest studies provided ‘clear pre-clinical proof-of-concept’ that its exosome technology can deliver therapeutic proteins to the corpus striatum
While pharmaceutical companies have identified different proteins that can help treat neurological illnesses, they often do not last long enough inside the body to be effective.
However, ReNeuron said studies performed with the University of Salamanca in Spain showed its exosome technology could deliver therapeutic proteins to areas of the brain at a higher level than administering a protein by itself.
